Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy

Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy

BackgroundHuman epidermal growth factor receptor 2(HER-2) is the most prominent therapeutic target for gastric (G)/gastroesophageal junction (GEJ) cancer. Guidelines recommend its use for treating G/GEJ cancers. However, targeted therapy did not significantly improve survival outcomes compared to th...

Full description

Saved in:
Bibliographic Details
Main Authors: Huanhuan Li, Chao Ren, Donghai Cui, Tao Wu, Zhiyong Nie
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Immunology
Subjects:
HER-2
immunotherapy
neoadjuvant therapy
gastric cancer
gastroesophageal junction adenocarcinoma
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1555074/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items